

Removal of temporary benefit from the Alberta Drug Benefit List (ADBL)

Due to the shortages for Teva-Cephalexin 125 25 mg/ml Oral Suspension (DIN 00342106) and Teva-Cephalexin 250 50 mg/ml Oral Suspension (DIN 00342092) manufactured by Teva Canada Limited, Lupin-Cephalexin 50 mg/ml Oral Suspension (DIN 02469189) manufactured by Lupin Pharma Canada Limited was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Teva Canada Limited has advised Alberta Blue Cross that the shortages for Teva-Cephalexin 125 25 mg/ml Oral Suspension (DIN 00342106) and Teva-Cephalexin 250 50 mg/ml Oral Suspension (DIN 00342092) have been resolved.

As a result, Lupin-Cephalexin 50 mg/ml Oral Suspension (DIN 02469189) will no longer be considered a temporary benefit for the *ADBL* after **January 4, 2021**. The following grouping was removed from the Critical Supply Product List **November 27, 2020**.

Product supply shortages addressed for Alberta Drug Benefit List (ADBL)

Alberta Blue Cross has been advised that the shortages for the following products have been resolved by their respective manufacturers.

DIN/NPN	Product description	Manufacturer
02456311	Ach-Olmesartan 20 mg Tablet	Accord Healthcare Inc.
02453452	Apo-Olmesartan 20 mg Tablet	Apotex Inc.
02461307	pms-Olmesartan 20 mg Tablet	Pharmascience Inc.
02443414	Sandoz Olmesartan 20 mg Tablet	Sandoz Canada Inc.

Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective January 4, 2021. The following grouping was removed from the Critical Supply Product List **November 27, 2020**.

OLMESARTAN MEDOXOMIL

20 MG TABLET

00002456311	ACH-OLMESARTAN	AHI	\$ 0.3019
00002442191	ACT OLMESARTAN	APH	\$ 0.3019
00002453452	APO-OLMESARTAN	APX	\$ 0.3019
00002443864	AURO-OLMESARTAN	AUR	\$ 0.3019
00002461641	JAMP-OLMESARTAN	JPC	\$ 0.3019
00002461307	PMS-OLMESARTAN	PMS	\$ 0.3019
00002443414	SANDOZ OLMESARTAN	SDZ	\$ 0.3019
00002318660	OLMETEC	MFC	\$ 1.1441

... continued from previous page

Alberta Blue Cross has been advised that the shortages for the following products have been resolved by their respective manufacturers.

DIN/NPN	Product description	Manufacturer
02456338	Ach-Olmesartan 40 mg Tablet	Accord Healthcare Inc.
02453460	Apo-Olmesartan 40 mg Tablet	Apotex Inc.
02443872	Auro-Olmesartan 40 mg Tablet	Auro Pharma Inc.
02461668	Jamp-Olmesartan 40 mg Tablet	Jamp Pharma Corporation
02461315	pms-Olmesartan 40 mg Tablet	Pharmascience Inc.
02443422	Sandoz Olmesartan 40 mg Tablet	Sandoz Canada Inc.

Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **January 13, 2021**. The following grouping was removed from the Critical Supply Product List **December 14, 2020**.

OLMESARTAN MEDOXOMIL

40 MG TABLET

00002456338	ACH-OLMESARTAN	AHI	\$ 0.3019
00002442205	ACT OLMESARTAN	APH	\$ 0.3019
00002453460	APO-OLMESARTAN	APX	\$ 0.3019
00002443872	AURO-OLMESARTAN	AUR	\$ 0.3019
00002461668	JAMP-OLMESARTAN	JPC	\$ 0.3019
00002461315	PMS-OLMESARTAN	PMS	\$ 0.3019
00002443422	SANDOZ OLMESARTAN	SDZ	\$ 0.3019
00002318660	OLMETEC	MFC	\$ 1.1441

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • 403-294-4041 (Calgary and area) • 1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area) • FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims. Visit ab.bluecross.ca/providers/pharmacy-home.php

